Letrozole Induced Hypercalcemia in a Patient with Breast Cancer
Hypersecretion of PTHrP is a relatively common cause of malignancy-related hypercalcemia. However, there is only one case report of letrozole induced hypercalcemia. A 52-year-old female patient was referred to our clinic because of the recent discovery of hypercalcemia (11.0 mg/dL). The patient had...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2014/608585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850232578050621440 |
|---|---|
| author | Suleyman Hilmi Ipekci Suleyman Baldane Ercument Ozturk Murat Araz Huseyin Korkmaz Fatih Colkesen Levent Kebapcilar |
| author_facet | Suleyman Hilmi Ipekci Suleyman Baldane Ercument Ozturk Murat Araz Huseyin Korkmaz Fatih Colkesen Levent Kebapcilar |
| author_sort | Suleyman Hilmi Ipekci |
| collection | DOAJ |
| description | Hypersecretion of PTHrP is a relatively common cause of malignancy-related hypercalcemia. However, there is only one case report of letrozole induced hypercalcemia. A 52-year-old female patient was referred to our clinic because of the recent discovery of hypercalcemia (11.0 mg/dL). The patient had a history of left breast carcinoma. She had started a course of letrozole (aromatase inhibitor; 2.5 mg dose/day) ten months earlier. Patient’s parathyroid hormone-related protein levels were normal and a bone scintigram revealed no evidence of skeletal metastasis. Other potential causes of high calcium levels were ruled out. We recognized that, when letrozole was taken at one dose daily (2.5 mg), she had recurrent hypercalcemia. Our experience suggests that letrozole may precipitate hypercalcemia in a patient with breast cancer. |
| format | Article |
| id | doaj-art-0aafa6f2ead641a2b0cf2ca2cbb12e1a |
| institution | OA Journals |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-0aafa6f2ead641a2b0cf2ca2cbb12e1a2025-08-20T02:03:08ZengWileyCase Reports in Oncological Medicine2090-67062090-67142014-01-01201410.1155/2014/608585608585Letrozole Induced Hypercalcemia in a Patient with Breast CancerSuleyman Hilmi Ipekci0Suleyman Baldane1Ercument Ozturk2Murat Araz3Huseyin Korkmaz4Fatih Colkesen5Levent Kebapcilar6Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, TurkeyDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, TurkeyDepartment of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, TurkeyDepartment of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, TurkeyDepartment of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, TurkeyDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Selcuk University, 42131 Konya, TurkeyHypersecretion of PTHrP is a relatively common cause of malignancy-related hypercalcemia. However, there is only one case report of letrozole induced hypercalcemia. A 52-year-old female patient was referred to our clinic because of the recent discovery of hypercalcemia (11.0 mg/dL). The patient had a history of left breast carcinoma. She had started a course of letrozole (aromatase inhibitor; 2.5 mg dose/day) ten months earlier. Patient’s parathyroid hormone-related protein levels were normal and a bone scintigram revealed no evidence of skeletal metastasis. Other potential causes of high calcium levels were ruled out. We recognized that, when letrozole was taken at one dose daily (2.5 mg), she had recurrent hypercalcemia. Our experience suggests that letrozole may precipitate hypercalcemia in a patient with breast cancer.http://dx.doi.org/10.1155/2014/608585 |
| spellingShingle | Suleyman Hilmi Ipekci Suleyman Baldane Ercument Ozturk Murat Araz Huseyin Korkmaz Fatih Colkesen Levent Kebapcilar Letrozole Induced Hypercalcemia in a Patient with Breast Cancer Case Reports in Oncological Medicine |
| title | Letrozole Induced Hypercalcemia in a Patient with Breast Cancer |
| title_full | Letrozole Induced Hypercalcemia in a Patient with Breast Cancer |
| title_fullStr | Letrozole Induced Hypercalcemia in a Patient with Breast Cancer |
| title_full_unstemmed | Letrozole Induced Hypercalcemia in a Patient with Breast Cancer |
| title_short | Letrozole Induced Hypercalcemia in a Patient with Breast Cancer |
| title_sort | letrozole induced hypercalcemia in a patient with breast cancer |
| url | http://dx.doi.org/10.1155/2014/608585 |
| work_keys_str_mv | AT suleymanhilmiipekci letrozoleinducedhypercalcemiainapatientwithbreastcancer AT suleymanbaldane letrozoleinducedhypercalcemiainapatientwithbreastcancer AT ercumentozturk letrozoleinducedhypercalcemiainapatientwithbreastcancer AT murataraz letrozoleinducedhypercalcemiainapatientwithbreastcancer AT huseyinkorkmaz letrozoleinducedhypercalcemiainapatientwithbreastcancer AT fatihcolkesen letrozoleinducedhypercalcemiainapatientwithbreastcancer AT leventkebapcilar letrozoleinducedhypercalcemiainapatientwithbreastcancer |